BioSpace News Archive

Increasing awareness about early cancer diagnosis, rising prevalence of various types of cancers, and growing demand for precision medicine are some factors expected to drive global tumor genomics market growth.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced that management will be participating in the upcoming Stifel Jaws and Paws Conference.

Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.

Theseus Pharmaceuticals, Inc. announced that the company will participate virtually in the H.C. Wainwright Global Investment Conference taking place May 23-26, 2022 and in-person in the Jefferies Healthcare Conference taking place June 8-10, 2022.

This acquisition solidifies CellCarta’s leadership position in proteomics services with a unique combination of validated set of reagents and multiplex assays, including pathway specific off-the-shelf panels, allowing for clinical protein quantification covering a comprehensive range of immuno-oncology targets.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the Company’s commitment to complying with the NASDAQ listing requirements on board diversity by August 1, 2022.

Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Cyanocobalamin Injection to its injectable drug portfolio.

To support the Greater Boston biotech ecosystem, Thermo Fisher Scientific is joining forces with biotech incubator LabShares Newton to provide instruments, lab equipment and consumables to help early-stage life sciences companies accelerate their

Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO, Murray S. Kessler and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Credit Suisse HALO Investment Summit held in New York City on Wednesday, May 25th.

Occlutech Holding AG Occlutech Holding AG (Occlutech), a leading specialist provider of minimally invasive structural heart implants, has signed an exclusive distribution agreement with B. Braun Interventional Systems Inc. (BIS) as an important next step in Occlutech’s commercial development in the US.